Free tool
FAERS Monitor: Loreev Xr
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 214826 or its brand name (Loreev Xr, Lorazepam). Reports on generic versions are filed under their own applications.
Reports
132,454
Serious
104,627
79% of reports
Hospitalization
56,944
Death reported
20,049
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective9,356
- fatigue9,067
- nausea8,908
- off label use7,927
- diarrhoea7,263
- dyspnoea6,330
- vomiting6,047
- headache5,884
- dizziness5,685
- anxiety5,680
- pain5,632
- death4,866
- asthenia4,820
- fall4,791
- pyrexia4,462
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1,777 |
| 2005 | 2,009 |
| 2006 | 1,920 |
| 2007 | 1,850 |
| 2008 | 2,103 |
| 2009 | 2,447 |
| 2010 | 3,536 |
| 2011 | 3,806 |
| 2012 | 4,683 |
| 2013 | 3,797 |
| 2014 | 4,705 |
| 2015 | 7,017 |
| 2016 | 7,670 |
| 2017 | 8,448 |
| 2018 | 10,305 |
| 2019 | 10,135 |
| 2020 | 9,963 |
| 2021 | 8,953 |
| 2022 | 8,543 |
| 2023 | 7,941 |
| 2024 | 8,189 |
| 2025 | 7,553 |
| 2026 | 5,100 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,921,705 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| anxietySignal | 5,680 | 3.2 | 3.1 | 8,601 |
| fallSignal | 4,791 | 2.3 | 2.2 | 3,542 |
| pyrexiaSignal | 4,462 | 2.1 | 2.0 | 2,446 |
| vomitingSignal | 6,047 | 2.1 | 2.0 | 3,310 |
| astheniaSignal | 4,820 | 2.0 | 2.0 | 2,601 |
| fatigue | 9,067 | 1.9 | 1.8 | 3,695 |
| dizziness | 5,685 | 1.8 | 1.8 | 2,123 |
| nausea | 8,908 | 1.8 | 1.8 | 3,229 |
| diarrhoea | 7,263 | 1.8 | 1.8 | 2,611 |
| dyspnoea | 6,330 | 1.8 | 1.7 | 2,217 |
| headache | 5,884 | 1.5 | 1.5 | 984 |
| pain | 5,632 | 1.5 | 1.4 | 833 |
| off label use | 7,927 | 1.4 | 1.4 | 1,108 |
| drug ineffective | 9,356 | 1.1 | 1.1 | 144 |
| death | 4,866 | 0.9 | 0.9 | 60 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.